Physician Assistant

Physician Assistant
Audio Summaries

The literature in physician assistant doesn't slow down, and the papers you skip might be the ones that change your practice. OSLR turns the journals you'd read if you had the time into 3-minute audio summaries. Listen on your commute, between cases, whenever.

6 active journals360 audio summaries

Recent summaries

The latest articles summarized from physician assistant journals.

The Oncology Care Model and Medicare Payments, Utilization, and Quality

JAMA|Mar 25, 2026

The authors aimed to evaluate the impact of the Oncology Care Model (OCM) on Medicare spending, utilization, and quality of care for patients undergoing chemotherapy. They found that while the OCM was associated with modest reductions in Medicare payments during treatment episodes, it did not significantly improve care quality, and ultimately resulted in a net loss to Medicare due to enhanced services and performance-based payments.

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

The New England journal of medicine|Mar 25, 2026

This study aimed to evaluate the efficacy of the oral PCSK9 inhibitor enlicitide in reducing LDL cholesterol levels in adults with a history of atherosclerotic cardiovascular disease or at risk for such events. The results demonstrated that enlicitide significantly lowered LDL cholesterol levels compared to placebo at both 24 and 52 weeks, with no notable difference in adverse events between the groups.

Home based, tailored intervention to reduce rate of falls after stroke (FAST): randomised trial

BMJ (Clinical research ed.)|Mar 24, 2026

The study aimed to evaluate the effectiveness of a multidisciplinary, home-based intervention in reducing falls among community-dwelling individuals who have experienced a stroke. Results indicated that the intervention led to a significant 33% reduction in the rate of falls over 12 months, alongside improvements in self-efficacy, mobility, community participation, and balance. These findings suggest that tailored interventions can effectively mitigate fall risks in this population.

Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial

Lancet (London, England)|Mar 24, 2026

The authors conducted a phase 3 trial (TORPEdO) to compare the clinical benefits of intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) in patients with locally advanced oropharyngeal squamous cell carcinoma, specifically assessing treatment-related effects on physical function and quality of life. The results indicated that both treatment modalities yielded similar outcomes regarding late physical quality of life, gastrostomy-tube dependence, disease control, and overall survival, suggesting that IMRT remains the standard of care in settings where IMPT is not routinely utilized.

Transesophageal Echocardiography During CPR in Patients With Out-of-Hospital Cardiac Arrest: The EXECT-CPR Randomized Clinical Trial

JAMA internal medicine|Mar 23, 2026

The authors aimed to determine whether transesophageal echocardiography (TEE) guidance during cardiopulmonary resuscitation (CPR) could improve outcomes in patients with nontraumatic out-of-hospital cardiac arrest compared to conventional CPR techniques. The study found no significant differences in the primary outcome of sustained return of spontaneous circulation or other secondary outcomes between the TEE-guided and conventional CPR groups, although the TEE group showed higher intra-CPR end-tidal carbon dioxide levels. These findings suggest that while TEE-guided CPR did not enhance clinical outcomes, it may offer hemodynamic benefits without increasing adverse events.

The Inherited Basis of Coronary Artery Disease

The New England journal of medicine|Mar 23, 2026

The authors investigate the genetic underpinnings of coronary artery disease (CAD) and how these insights can enhance risk prediction, prevention, and treatment strategies. They highlight the significance of both monogenic and polygenic factors in CAD, emphasizing the potential of polygenic risk scores to improve individual risk assessment. Key questions remain about the practical application, cost-effectiveness, and integration of these genetic insights into clinical practice.

Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies

JAMA internal medicine|Mar 23, 2026

The authors aimed to evaluate the health benefits, costs, and cost-effectiveness of jail-based interventions for hepatitis C virus (HCV) elimination among people who inject drugs. Their analysis found that a combined strategy of testing, treatment, and navigation services significantly reduced HCV infections and related deaths, achieving an incremental cost-effectiveness ratio of $11,000 per quality-adjusted life-year gained, which is well below typical cost-effectiveness thresholds. The study concludes that implementing these interventions in jails is a viable and cost-effective public health strategy.

Diagnosis and Management of Resistant Hypertension: A Review

JAMA|Mar 23, 2026

The authors aim to address the diagnosis and management of resistant hypertension, which affects approximately 10% of patients despite treatment. They highlight the importance of excluding factors such as white-coat hypertension and medication nonadherence, and recommend lifestyle modifications, optimized pharmacologic therapy, and interventions like spironolactone and renal denervation to effectively lower blood pressure in these patients.

Primary sclerosing cholangitis

Lancet (London, England)|Mar 23, 2026

This article investigates the clinical features, pathogenesis, and management challenges of primary sclerosing cholangitis (PSC), a rare chronic liver disease often associated with inflammatory bowel disease. The authors aim to clarify the disease's variable presentation, the role of genetic and environmental factors, including the intestinal microbiome, and the limited treatment options available. The seminar highlights the need for a deeper understanding of PSC to improve patient outcomes and management strategies.

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

Lancet (London, England)|Mar 22, 2026

The evoke and evoke+ trials aimed to evaluate the efficacy and safety of oral semaglutide (14 mg) in individuals with early-stage symptomatic Alzheimer's disease. The results indicated that semaglutide did not significantly slow clinical progression compared to placebo, and while safety profiles were consistent with other indications, the treatment did not demonstrate the expected benefits in this population.

Start listening to physician assistant research

14-day free trial. Pick your journals and go.